|
Metformin
|
Medicine for type 2 diabetes
|
Breast cancer
|
Inhibiting FAO at clinical doses
|
[117]
|
|
Etomoxir
|
Retired from phase II clinical trial for diabetes and heart failures
|
Bladder cancer
|
Suppressing tumor progression and inducing cell cycle arrest via PPARγ-mediated pathway
|
[118]
|
|
Malignant glioma
|
Targeting FAO to reduce energy production and cellular proliferation in glioma cells
|
[119]
|
|
Leukemia
|
Decreasing leukemia cells proliferation and sensitizing leukemia cells to apoptosis induced by ABT-737 and Nutlin 3a
|
[120]
|
|
Peritoneal metastatic colorectal cancer
|
Inhibiting cancer-associated fibroblast FAO to decline colorectal cancer metastasis
|
[121]
|
|
Epithelial-derived high-grade serous ovarian cancer
|
Targeting FAO to promote anoikis and inhibit ovarian cancer progression
|
[37]
|
|
Nasopharyngeal carcinoma
|
Targeting FAO to sensitize cancer to radiation therapy
|
[115]
|
|
Ranolazine
|
Medicine for angina pectoris in Europe and United States
|
Leukemia
|
Decreasing leukemia cells proliferation and sensitizing leukemia cells to apoptosis induced by ABT-737 and Nutlin 3a
|
[120]
|
|
Perhexiline
|
Medicine for angina pectoris in Australia and Asia
|
Leukemia
|
Targeting CPT to eliminate chronic lymphocytic leukemia cells in stromal microenvironment
|
[122]
|
